Trevi Therapeutics (TRVI) Invested Capital (2021 - 2023)

Trevi Therapeutics' Invested Capital history runs 3 years deep, the most recent figure standing at $153000.0 for Q4 2023.

• On a quarterly basis, Invested Capital fell 97.81% year-over-year to $153000.0 in Q4 2023; TTM through Sep 2024 was $153000.0, a 98.94% decrease from a year earlier, with the FY2023 full-year figure at $153000.0, down 97.81% from the prior year.
• Invested Capital fell to $153000.0 in Q4 2023 per TRVI's latest filing, from $7.5 million in the prior quarter.
• Across five years, Invested Capital topped out at $7.5 million in Q1 2023 and bottomed at $153000.0 in Q4 2023.
• The 3-year median for Invested Capital is $6.4 million (2021), against an average of $4.8 million.
• Across the five-year window, Invested Capital jumped 1100.69% in 2022 and sank 97.81% in 2023, its largest moves.
• Year by year, Invested Capital stood at $5.8 million in 2021, then climbed by 20.01% to $7.0 million in 2022, then sank by 97.81% to $153000.0 in 2023.
• Per Business Quant, the three latest TRVI Invested Capital figures stand at $153000.0 (Q4 2023), $7.5 million (Q1 2023), and $7.0 million (Q4 2022).